CovalX and ASPEC Technologies said this week that they have signed a distribution agreement to sell CovalX's mass spec-based protein interaction and protein characterization tools into the greater China market.
The agreement combines CovalX's products with ASPEC's commercial partnerships and infrastructure in this region, providing ASPEC customers with exclusive access to CovalX's protein analysis tools, the companies said.
CovalX's MALDI mass spec-based HM3 platform allows for protein-protein analyses including stoichiometry, biotherapeutic aggregation, epitope mapping, and immunocomplex characterization.
The deal covers ASPEC customers in mainland China, Hong Kong, Macau and Taiwan. Financial and other terms were not disclosed.